This study is for men who have prostate cancer that has spread outside of the prostate gland and is no longer responding to hormone removal therapy. This study is designed to determine if a new drug combination will help to control the cancer. The medicines being used, docetaxel and diethylstilbestrol(DES), have been given to patients with prostate cancer and each drug has demonstrated activity in prostae cancer, either used alone or in other combinations. The objective of this study is to determine the effect of this drug combination on the prostate cancer and its response to disease progression.

Condition	Intervention	Phase
Prostate Cancer	Drug: Docetaxel and Diethylstilbestrol (DES)	Phase II

Further Study Details: 

Primary Outcomes: To evaluate the PSA and objective response of androgen independent prostate cancer stage D3 in patients treated with docetaxel and DES
Secondary Outcomes: 1. To evaluate disease specific and overall survival; 2. To evaluate the time to progression of disease; 3. To determine the risk of cardiovascular complications associated with DES plus aspirin and warfarin 2 mg daily; 4. To measure these regimen''''s toxicity and impact on quality of life measures.
Expected Total Enrollment:  30

This is sigle arm phase II trial of docetaxel and diethylstilbestrol for patients with symptomatic stage D3 androgen independent prostate cancer. Patients will receive docetaxel weekly for 10 cycles (each cycle consits of treatment for 3 weeks our of every 4) and DES daily for 40 weeks or until there is evidence of disease progression, whichever occurs first. Patients will be followed to determine PSA and objective response. Additional endpoints include time to progression, disease specific survival and overall survival. Disease progression will be defined as 2 consecutive increases in PSA and/or tumor growth as evidenced by examination or radiologic evaluation. Other secondary objectives will be to determine the toxicity, and impact on quality of life of this regimen.

Ages Eligible for Study:  21 Years   -   83 Years,  Genders Eligible for Study:  Male

Criteria

Inclusion Criteria:

• Patients meeting all of the following criteria are eligible for the trial.

  1. Men 18 years of age or older with a histologically confirmed diagnosis of adenocarcinoma of the prostate consistent with stage D3.
  2. Prior therapy with medical or surgical castration and evidence of castrate levels of testosterone
  3. Discontinuation of nonsteroidal antiandrogens more than 6 weeks prior to evaluation for progression. It is not a requirement that nonsteroidal antiandrogen therapy be used prior to enrollment.

  4. Androgen independent disease as defined by one of the following after androgen ablation and withdrawal from nonsteroidal antiandrogen if initiated (> 6 weeks after discontinuation);

     • PSA must be greater than 5 ng/ml and increasing as demonstrated by two consecutive increasing PSA levels over 5 ng/ml. Each PSA measurement must be taken at least one week apart.
     • Increase in measurable disease within one month of enrollment
     • Worsening of bone scan abnormalities within two months of enrollment and greater than four months since initiation of LHRH agonist.
  5. Performance status < 3 by the ECOG scale (see Appendix B).
  6. Patients must be informed of the investigational nature of the study and sign an informed consent form.
  7. Life expectancy must be *3 months.

  8. Laboratory values must be as follows:

     White blood cell count: * 3,000/mm3 Absolute granulocyte count: * 1,500/mm3 Platelets: * 100,000/mm3 Hemoglobin * 8g/dL Serum creatinine: * 1.5 x ULN AST * 2 x ULN ALT: * 2 x ULN Serum calcium: * ULN Total bilirubin: * 1.5 x ULN

  9. Patient must be willing to consent to using effective contraception while on treatment and for three months after completion of therapy.

Exclusion criteria Patients meeting any of the following criteria will not be eligible for the trial.

1. Patients who have received PC-SPES, DES, mitoxantrone or docetaxel therapy.
2. Patients who have received prior chemotherapy of any type or are receiving any other investigational therapy.
3. Patients with evidence of recent deep venous thrombosis, pulmonary emboli, unstable angina or clinical congestive heart failure.
4. Patients with a prior history of myocardial infarction, pulmonary embolism, CVA or atrial fibrillation.
5. Patients with evidence of active angina as evidenced by chest pain responsive to sublingual nitroglycerin or other anginal equivalent.
6. Patients with known evidence of brain metastases or carcinomatous meningitis.
7. Patients with a history of other cancers except curatively-treated non-melanomatous skin cancer. Other cured tumors may be entered after discussion with and approval of the study chair.
8. Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.
9. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.
10. Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 must be excluded.
11. Histologic evidence of small cell carcinoma of the prostate.
12. Patients with current peripheral neuropathy of any etiology that is greater than Grade I.
13. Patients with contraindications to anti-coagulation.

Exclusion Criteria:

-

Please refer to this study by ClinicalTrials.gov identifier  NCT00136526

Bruce Montgomery, MD      206-764-2709    rbmontgo@u.washington.edu
Vivian Markle, RN      206-667-4765    vmarkle@fhcrc.org

Oregon
      Oregon Health and Science University, Portland,  Oregon,  97239,  United States; Recruiting
Washington
      University of Washington, Seattle,  Washington,  98109,  United States; Recruiting

Study chairs or principal investigators

Bruce Montgomery, MD,  Principal Investigator,  University of Washington   

Study ID Numbers:  02-4599-V; FHCRC-UW-02-4599-V
Last Updated:  August 26, 2005
Record first received:  August 25, 2005
ClinicalTrials.gov Identifier:  NCT00136526
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-08-30